Test Bank For Pharmacotherapeutics for Nurse Practitioner Prescribers 3rd Edition by Teri Moser Woo
Original price was: $65.00.$40.00Current price is: $40.00.
Test Bank For Pharmacotherapeutics For Nurse Practitioner Prescribers 3rd Edition by Teri Moser Woo is an essential tool for those nurse practitioners who wish to improve their prescribing skills. The Test Bank provides users with the information they need to make sure that they are prescribing medications safely and effectively. It includes detailed information on drugs, including their indications, contraindications, side effects, and drug interactions.
In addition, the Test Bank includes a comprehensive review of pharmacokinetics and pharmacodynamics. With its clear and concise explanations, the Test Bank is an invaluable resource for those nurse practitioners who want to ensure that they are providing the best possible care for their patients.
Digital item No Waiting Time Instant Download
ISBN-13: 978-0803622357 ISBN-10: 080362235X
Description
Test Bank For Pharmacotherapeutics for Nurse Practitioner Prescribers 3rd Edition by Teri Moser Woo
Chapter 2: Review of Basic Principles of Pharmacology
Multiple Choice
Identify the choice that best completes the statement or answers the question.
____ 1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to prescribing because:
|
A. |
Distribution of drugs to target tissue may be affected |
|
B. |
The solubility of the drug will not match the site of absorption |
|
C. |
There will be less free drug available to generate an effect |
|
D. |
Drugs bound to albumin are readily excreted by the kidney |
____ 2. Drugs that have a significant first-pass effect:
|
A. |
Must be given by the enteral (oral) route only |
|
B. |
Bypass the hepatic circulation |
|
C. |
Are rapidly metabolized by the liver and may have little if any desired action |
|
D. |
Are converted by the liver to more active and fat-soluble forms |
____ 3. The route of excretion of a volatile drug will likely be:
|
A. |
The kidneys |
|
B. |
The lungs |
|
C. |
The bile and feces |
|
D. |
The skin |
____ 4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the drug. Storage reservoirs:
|
A. |
Assure that the drug will reach its intended target tissue |
|
B. |
Are the reason for giving loading doses |
|
C. |
Increase the length of time a drug is available and active |
|
D. |
Are most common in collagen tissues |
____ 5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
|
A. |
Propensity to go to the target receptor |
|
B. |
Biological half-life |
|
C. |
Pharmacodynamics |
|
D. |
Safety and side effects |
____ 6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the prescription. This is considered a loading dose. A loading dose:
|
A. |
Rapidly achieves drug levels in the therapeutic range |
|
B. |
Requires four to five half-lives to attain |
|
C. |
Is influenced by renal function |
|
D. |
Is directly related to the drug circulating to the target tissues |
____ 7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic effect is the:
|
A. |
Minimum adverse effect level |
|
B. |
Peak of action |
|
C. |
Onset of action |
|
D. |
Therapeutic range |
____ 8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
|
A. |
When the drug has a wide therapeutic range |
|
B. |
When the drug will be administered for a short time only |
|
C. |
When there is a high correlation between the dose and saturation of receptor sites |
|
D. |
To determine if a drug is in the therapeutic range |
____ 9. A laboratory result indicates the peak level for a drug is above the minimum toxic concentration. This means that the:
|
A. |
Concentration will produce therapeutic effects |
|
B. |
Concentration will produce an adverse response |
|
C. |
Time between doses must be shortened |
|
D. |
Duration of action of the drug is too long |
____ 10. Drugs that are receptor agonists may demonstrate what property?
|
A. |
Irreversible binding to the drug receptor site |
|
B. |
Up-regulation with chronic use |
|
C. |
Desensitization or down-regulation with continuous use |
|
D. |
Inverse relationship between drug concentration and drug action |
____ 11. Drugs that are receptor antagonists, such as beta blockers, may cause:
|
A. |
Down-regulation of the drug receptor |
|
B. |
An exaggerated response if abruptly discontinued |
|
C. |
Partial blockade of the effects of agonist drugs |
|
D. |
An exaggerated response to competitive drug agonists |
____ 12. Factors that affect gastric drug absorption include:
|
A. |
Liver enzyme activity |
|
B. |
Protein-binding properties of the drug molecule |
|
C. |
Lipid solubility of the drug |
|
D. |
Ability to chew and swallow |
____ 13. Drugs administered via intravenous (IV) route:
|
A. |
Need to be lipid soluble in order to be easily absorbed |
|
B. |
Begin distribution into the body immediately |
|
C. |
Are easily absorbed if they are nonionized |
|
D. |
May use pinocytosis to be absorbed |
____ 14. When a medication is added to a regimen for a synergistic effect, the combined effect of the drugs is:
|
A. |
The sum of the effects of each drug individually |
|
B. |
Greater than the sum of the effects of each drug individually |
|
C. |
Less than the effect of each drug individually |
|
D. |
Not predictable, as it varies with each individual |
____ 15. Which of the following statements about bioavailability is true?
|
A. |
Bioavailability issues are especially important for drugs with narrow therapeutic ranges or sustained release mechanisms. |
|
B. |
All brands of a drug have the same bioavailability. |
|
C. |
Drugs that are administered more than once a day have greater bioavailability than drugs given once daily. |
|
D. |
Combining an active drug with an inert substance does not affect bioavailability. |
____ 16. Which of the following statements about the major distribution barriers (blood-brain or fetal-placental) is true?
|
A. |
Water soluble and ionized drugs cross these barriers rapidly. |
|
B. |
The blood-brain barrier slows the entry of many drugs into and from brain cells. |
|
C. |
The fetal-placental barrier protects the fetus from drugs taken by the mother. |
|
D. |
Lipid soluble drugs do not pass these barriers and are safe for pregnant women. |
____ 17. Drugs are metabolized mainly by the liver via Phase I or Phase II reactions. The purpose of both of these types of reactions is to:
|
A. |
Inactivate prodrugs before they can be activated by target tissues |
|
B. |
Change the drugs so they can cross plasma membranes |
|
C. |
Change drug molecules to a form that an excretory organ can excrete |
|
D. |
Make these drugs more ionized and polar to facilitate excretion |
____ 18. Once they have been metabolized by the liver, the metabolites may be:
|
A. |
More active than the parent drug |
|
B. |
Less active than the parent drug |
|
C. |
Totally “deactivated” so that they are excreted without any effect |
|
D. |
All of the above |
____ 19. All drugs continue to act in the body until they are changed or excreted. The ability of the body to excrete drugs via the renal system would be increased by:
|
A. |
Reduced circulation and perfusion of the kidney |
|
B. |
Chronic renal disease |
|
C. |
Competition for a transport site by another drug |
|
D. |
Unbinding a nonvolatile drug from plasma proteins |
____ 20. Steady state is:
|
A. |
The point on the drug concentration curve when absorption exceeds excretion |
|
B. |
When the amount of drug in the body remains constant |
|
C. |
When the amount of drug in the body stays below the MTC |
|
D. |
All of the above |
____ 21. Two different pain meds are given together for pain relief. The drug-drug interaction is:
|
A. |
Synergistic |
|
B. |
Antagonistic |
|
C. |
Potentiative |
|
D. |
Additive |
____ 22. Actions taken to reduce drug-drug interaction problems include all of the following EXCEPT:
|
A. |
Reducing the dose of one of the drugs |
|
B. |
Scheduling their administration at different times |
|
C. |
Prescribing a third drug to counteract the adverse reaction of the combination |
|
D. |
Reducing the dosage of both drugs |
____ 23. Phase I oxidative-reductive processes of drug metabolism require certain nutritional elements. Which of the following would reduce or inhibit this process?
|
A. |
Protein malnutrition |
|
B. |
Iron deficiency anemia |
|
C. |
Both A and B |
|
D. |
Neither A nor B |
____ 24. The time required for the amount of drug in the body to decrease by 50% is called:
|
A. |
Steady state |
|
B. |
Half-life |
|
C. |
Phase II metabolism |
|
D. |
Reduced bioavailability time |
____ 25. An agonist activates a receptor and stimulates a response. When given frequently over time the body may:
|
A. |
Up-regulate the total number of receptors |
|
B. |
Block the receptor with a partial agonist |
|
C. |
Alter the drug’s metabolism |
|
D. |
Down-regulate the numbers of that specific receptor |
____ 26. Drug antagonism is best defined as an effect of a drug that:
|
A. |
Leads to major physiologic psychological dependence |
|
B. |
Is modified by the concurrent administration of another drug |
|
C. |
Cannot be metabolized before another dose is administered |
|
D. |
Leads to a decreased physiologic response when combined with another drug |
____ 27. Instructions to a client regarding self-administration of oral enteric-coated tablets should include which of the following statements?
|
A. |
“Avoid any other oral medicines while taking this drug.” |
|
B. |
“If swallowing this tablet is difficult, dissolve it in 3 ounces of orange juice.” |
|
C. |
“The tablet may be crushed if you have any difficultly taking it.” |
|
D. |
“To achieve best effect, take the tablet with at least 8 ounces of fluid.” |
____ 28. The major reason for not crushing a sustained release capsule is that, if crushed, the coated beads of the drugs could possibly result in:
|
A. |
Disintegration |
|
B. |
Toxicity |
|
C. |
Malabsorption |
|
D. |
Deterioration |
____ 29. Which of the following substances is the most likely to be absorbed in the intestines rather than in the stomach?
|
A. |
Sodium bicarbonate |
|
B. |
Ascorbic acid |
|
C. |
Salicylic acid |
|
D. |
Glucose |
____ 30. Which of the following variables is a factor in drug absorption?
|
A. |
The smaller the surface area for absorption, the more rapidly the drug is absorbed. |
|
B. |
A rich blood supply to the area of absorption leads to better absorption. |
|
C. |
The less soluble the drug, the more easily it is absorbed. |
|
D. |
Ionized drugs are easily absorbed across the cell membrane. |
____ 31. An advantage of prescribing a sublingual medication is that the medication is:
|
A. |
Absorbed rapidly |
|
B. |
Excreted rapidly |
|
C. |
Metabolized minimally |
|
D. |
Distributed equally |
____ 32. Drugs that use CYP 3A4 isoenzymes for metabolism may:
|
A. |
Induce the metabolism of another drug |
|
B. |
Inhibit the metabolism of another drug |
|
C. |
Both A and B |
|
D. |
Neither A nor B |
____ 33. Therapeutic drug levels are drawn when a drug reaches steady state. Drugs reach steady state:
|
A. |
After the second dose |
|
B. |
After four to five half-lives |
|
C. |
When the patient feels the full effect of the drug |
|
D. |
One hour after IV administration |
____ 34. Up-regulation or hypersensitization may lead to:
|
A. |
Increased response to a drug |
|
B. |
Decreased response to a drug |
|
C. |
An exaggerated response if the drug is withdrawn |
|
D. |
Refractoriness or complete lack of response |
Chapter 2: Review of Basic Principles of Pharmacology
Answer Section
MULTIPLE CHOICE
1.ANS:APTS:1
2.ANS:CPTS:1
3.ANS:BPTS:1
4.ANS:CPTS:1
5.ANS:BPTS:1
6.ANS:APTS:1
7.ANS:CPTS:1
8.ANS:DPTS:1
9.ANS:BPTS:1
10.ANS:CPTS:1
11.ANS:BPTS:1
12.ANS:CPTS:1
13.ANS:BPTS:1
14.ANS:BPTS:1
15.ANS:APTS:1
16.ANS:BPTS:1
17.ANS:CPTS:1
18.ANS:DPTS:1
19.ANS:DPTS:1
20.ANS:BPTS:1
21.ANS:DPTS:1
22.ANS:CPTS:1
23.ANS:DPTS:1
24.ANS:BPTS:1
25.ANS:DPTS:1
26.ANS:BPTS:1
27.ANS:DPTS:1
28.ANS:BPTS:1
29.ANS:APTS:1
30.ANS:BPTS:1
31.ANS:APTS:1
32.ANS:CPTS:1
33.ANS:BPTS:1
34.ANS:CPTS:1
Related Products
Be the first to review “Test Bank For Pharmacotherapeutics for Nurse Practitioner Prescribers 3rd Edition by Teri Moser Woo”